Buy 2+ vials to unlock bundle savings (5% / 10% / 15%). Add more to reach $150 for free shipping.
Overview
Tirzepatide is a synthetic peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its dual-receptor mechanism has made it one of the most extensively studied compounds in metabolic research.
Mechanism
Tirzepatide activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Dual incretin receptor engagement is studied for downstream effects on metabolic signaling pathways in preclinical and clinical research models.
Areas of Active Scientific Research
Researchers continue to investigate Tirzepatide for its potential influence on metabolic regulation, glucose homeostasis, appetite signaling, energy balance, and body composition. Its unique pharmacological profile has positioned it as a significant advancement in incretin-based research.
Molecular Characteristics
- Molecular weight
- 4813.5 Da
- Formula
- C225H348N48O68
- Sequence
- 39 amino acid synthetic peptide (GIP/GLP-1 dual agonist scaffold)
- Appearance
- White to off-white lyophilized powder supplied in research vial format.
- Dose
- 15mg
- Grade
- Research grade (RUO)
Storage Recommendations
For laboratory research use only. Store lyophilized material at −20°C or below. Reconstitute and handle according to institutional SOPs for peptide research.
Purity
Target purity ≥99% by HPLC for this research-grade batch. See the Certificate of Analysis for batch-specific analytical results.
≥99.0%
Batch Number
Current batch identifier for traceability and COA lookup:
PL-TIR-15-26042
Date Tested: 2026-04-18
Certificate of Analysis
Tirzepatide 15mg · Third-party verified batch documentation
- Laboratory Name
- Independent Analytical Laboratory (ISO/IEC 17025)
- Purity %
- ≥99.0%
- Batch Number
- PL-TIR-15-26042
- Date Tested
- 2026-04-18
What a COA demonstrates
Batch-specific identity verification, purity by validated analytical methods (e.g. HPLC), and third-party laboratory testing records for the referenced lot.
What a COA does not demonstrate
Clinical efficacy, safety for human or veterinary use, or suitability for any application outside qualified laboratory research.
Quality Assurance
Every Prime Labs peptide undergoes rigorous quality control procedures and is accompanied by batch specific analytical documentation to support identity and purity verification.
References
Selected peer-reviewed literature for research context. Prime Labs citations do not constitute therapeutic claims.
- Frias J.P. et al. — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.
- Jastreboff A.M. et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.